Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

BGP-15 Protects Mitochondria in Acute, Acetaminophen Overdose Induced Liver Injury.

Sarnyai F, Szekerczés T, Csala M, Sümegi B, Szarka A, Schaff Z, Mandl J.

Pathol Oncol Res. 2019 Nov 8. doi: 10.1007/s12253-019-00721-1. [Epub ahead of print]

PMID:
31705481
2.

The Mitochondrial Targets of Neuroprotective Drug Vinpocetine on Primary Neuron Cultures, Brain Capillary Endothelial Cells, Synaptosomes, and Brain Mitochondria.

Svab G, Doczi J, Gerencser AA, Ambrus A, Gallyas F, Sümegi B, Tretter L.

Neurochem Res. 2019 Oct;44(10):2435-2447. doi: 10.1007/s11064-019-02871-9. Epub 2019 Sep 18.

3.

PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells.

Cseh AM, Fabian Z, Quintana-Cabrera R, Szabo A, Eros K, Soriano ME, Gallyas F, Scorrano L, Sumegi B.

Front Physiol. 2019 May 7;10:538. doi: 10.3389/fphys.2019.00538. eCollection 2019.

4.

PARP Inhibitor Protects Against Chronic Hypoxia/Reoxygenation-Induced Retinal Injury by Regulation of MAPKs, HIF1α, Nrf2, and NFκB.

Kovacs K, Vaczy A, Fekete K, Kovari P, Atlasz T, Reglodi D, Gabriel R, Gallyas F, Sumegi B.

Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1478-1490. doi: 10.1167/iovs.18-25936.

PMID:
30973576
5.

PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome.

Tapodi A, Bognar Z, Szabo C, Gallyas F, Sumegi B, Hocsak E.

Biochem Pharmacol. 2019 Apr;162:98-108. doi: 10.1016/j.bcp.2018.10.005. Epub 2018 Oct 6.

6.

Amiodarone's major metabolite, desethylamiodarone, induces apoptosis in human cervical cancer cells.

Bognar Z, Fekete K, Bognar R, Szabo A, Vass RA, Sumegi B.

Can J Physiol Pharmacol. 2018 Oct;96(10):1004-1011. doi: 10.1139/cjpp-2018-0113. Epub 2018 May 30.

PMID:
29847733
7.

Activation of mitochondrial fusion provides a new treatment for mitochondria-related diseases.

Szabo A, Sumegi K, Fekete K, Hocsak E, Debreceni B, Setalo G Jr, Kovacs K, Deres L, Kengyel A, Kovacs D, Mandl J, Nyitrai M, Febbraio MA, Gallyas F Jr, Sumegi B.

Biochem Pharmacol. 2018 Apr;150:86-96. doi: 10.1016/j.bcp.2018.01.038. Epub 2018 Feb 3.

8.

Desethylamiodarone-A metabolite of amiodarone-Induces apoptosis on T24 human bladder cancer cells via multiple pathways.

Bognar Z, Fekete K, Antus C, Hocsak E, Bognar R, Tapodi A, Boronkai A, Farkas N, Gallyas F Jr, Sumegi B, Szanto A.

PLoS One. 2017 Dec 8;12(12):e0189470. doi: 10.1371/journal.pone.0189470. eCollection 2017.

9.

Cardioprotective Effect of Resveratrol in a Postinfarction Heart Failure Model.

Riba A, Deres L, Sumegi B, Toth K, Szabados E, Halmosi R.

Oxid Med Cell Longev. 2017;2017:6819281. doi: 10.1155/2017/6819281. Epub 2017 Oct 3.

10.

PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway.

Hocsak E, Szabo V, Kalman N, Antus C, Cseh A, Sumegi K, Eros K, Hegedus Z, Gallyas F Jr, Sumegi B, Racz B.

Free Radic Biol Med. 2017 Jul;108:770-784. doi: 10.1016/j.freeradbiomed.2017.04.018. Epub 2017 Apr 27.

11.

Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors.

Cseh AM, Fábián Z, Sümegi B, Scorrano L.

Oncotarget. 2017 Jul 25;8(30):50221-50239. doi: 10.18632/oncotarget.16859. Review.

12.

Doxycycline protects against ROS-induced mitochondrial fragmentation and ISO-induced heart failure.

Riba A, Deres L, Eros K, Szabo A, Magyar K, Sumegi B, Toth K, Halmosi R, Szabados E.

PLoS One. 2017 Apr 6;12(4):e0175195. doi: 10.1371/journal.pone.0175195. eCollection 2017.

13.

Chronic PARP-1 inhibition reduces carotid vessel remodeling and oxidative damage of the dorsal hippocampus in spontaneously hypertensive rats.

Eros K, Magyar K, Deres L, Skazel A, Riba A, Vamos Z, Kalai T, Gallyas F Jr, Sumegi B, Toth K, Halmosi R.

PLoS One. 2017 Mar 24;12(3):e0174401. doi: 10.1371/journal.pone.0174401. eCollection 2017.

14.

Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegi B, Swanson RA, Szabo C.

Br J Pharmacol. 2018 Jan;175(2):192-222. doi: 10.1111/bph.13748. Epub 2017 Mar 26. Review.

15.

BGP-15 Protects against Oxidative Stress- or Lipopolysaccharide-Induced Mitochondrial Destabilization and Reduces Mitochondrial Production of Reactive Oxygen Species.

Sumegi K, Fekete K, Antus C, Debreceni B, Hocsak E, Gallyas F Jr, Sumegi B, Szabo A.

PLoS One. 2017 Jan 3;12(1):e0169372. doi: 10.1371/journal.pone.0169372. eCollection 2017.

16.

PARP inhibition and postinfarction myocardial remodeling.

Halmosi R, Deres L, Gal R, Eros K, Sumegi B, Toth K.

Int J Cardiol. 2016 Aug;217 Suppl:S52-9. doi: 10.1016/j.ijcard.2016.06.223. Epub 2016 Jun 28. Review.

PMID:
27392900
17.

Lack of cyclophilin D protects against the development of acute lung injury in endotoxemia.

Fonai F, Priber JK, Jakus PB, Kalman N, Antus C, Pollak E, Karsai G, Tretter L, Sumegi B, Veres B.

Biochim Biophys Acta. 2015 Dec;1852(12):2563-73. doi: 10.1016/j.bbadis.2015.09.004. Epub 2015 Sep 15.

18.

Role of mitochondrial network stabilisation by a human small heat shock protein in tumour malignancy.

Turi Z, Hocsak E, Racz B, Szabo A, Balogh A, Sumegi B, Gallyas F Jr.

J Cancer. 2015 Mar 25;6(5):470-6. doi: 10.7150/jca.11494. eCollection 2015.

19.

Cyclophilin D disruption attenuates lipopolysaccharide-induced inflammatory response in primary mouse macrophages.

Priber J, Fonai F, Jakus PB, Racz B, Chinopoulos C, Tretter L, Gallyas F Jr, Sumegi B, Veres B.

Biochem Cell Biol. 2015 Jun;93(3):241-50. doi: 10.1139/bcb-2014-0120. Epub 2015 Jan 23.

PMID:
25728038
20.

Anti-inflammatory effects of a triple-bond resveratrol analog: structure and function relationship.

Antus C, Radnai B, Dombovari P, Fonai F, Avar P, Matyus P, Racz B, Sumegi B, Veres B.

Eur J Pharmacol. 2015 Feb 5;748:61-7. doi: 10.1016/j.ejphar.2014.12.009. Epub 2014 Dec 18.

PMID:
25528327
21.

Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt.

Kiss T, Kovacs K, Komocsi A, Tornyos A, Zalan P, Sumegi B, Gallyas F Jr, Kovacs K.

PLoS One. 2014 Aug 18;9(8):e104890. doi: 10.1371/journal.pone.0104890. eCollection 2014.

22.

PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.

Deres L, Bartha E, Palfi A, Eros K, Riba A, Lantos J, Kalai T, Hideg K, Sumegi B, Gallyas F, Toth K, Halmosi R.

PLoS One. 2014 Jul 11;9(7):e102148. doi: 10.1371/journal.pone.0102148. eCollection 2014.

23.

Estradiol and isotype-selective estrogen receptor agonists modulate the mesocortical dopaminergic system in gonadectomized female rats.

Sárvári M, Deli L, Kocsis P, Márk L, Maász G, Hrabovszky E, Kalló I, Gajári D, Vastagh C, Sümegi B, Tihanyi K, Liposits Z.

Brain Res. 2014 Oct 2;1583:1-11. doi: 10.1016/j.brainres.2014.06.020. Epub 2014 Jun 26.

PMID:
24976584
24.

PARP inhibitor attenuated colony formation can be restored by MAP kinase inhibitors in different irradiated cancer cell lines.

Hocsak E, Cseh A, Szabo A, Bellyei S, Pozsgai E, Kalai T, Hideg K, Sumegi B, Boronkai A.

Int J Radiat Biol. 2014 Dec;90(12):1152-61. doi: 10.3109/09553002.2014.934927. Epub 2014 Nov 14.

PMID:
24937370
25.

A quinazoline-derivative compound with PARP inhibitory effect suppresses hypertension-induced vascular alterations in spontaneously hypertensive rats.

Magyar K, Deres L, Eros K, Bruszt K, Seress L, Hamar J, Hideg K, Balogh A, Gallyas F Jr, Sumegi B, Toth K, Halmosi R.

Biochim Biophys Acta. 2014 Jul;1842(7):935-44. doi: 10.1016/j.bbadis.2014.03.008. Epub 2014 Mar 19.

26.

[Mitochondria, oxidative stress and aging].

Szarka A, Bánhegyi G, Sümegi B.

Orv Hetil. 2014 Mar 23;155(12):447-52. doi: 10.1556/OH.2014.29852. Review. Hungarian.

PMID:
24631932
27.

PARP inhibition attenuates acute kidney allograft rejection by suppressing cell death pathways and activating PI-3K-Akt cascade.

Kalmar-Nagy K, Degrell P, Szabo A, Sumegi K, Wittmann I, Gallyas F Jr, Sumegi B.

PLoS One. 2013 Dec 3;8(12):e81928. doi: 10.1371/journal.pone.0081928. eCollection 2013.

28.

Quercetin increases the efficacy of glioblastoma treatment compared to standard chemoradiotherapy by the suppression of PI-3-kinase-Akt pathway.

Pozsgai E, Bellyei S, Cseh A, Boronkai A, Racz B, Szabo A, Sumegi B, Hocsak E.

Nutr Cancer. 2013;65(7):1059-66. doi: 10.1080/01635581.2013.810291. Epub 2013 Sep 13.

PMID:
24032376
29.

Antioxidant and anti-inflammatory effects in RAW264.7 macrophages of malvidin, a major red wine polyphenol.

Bognar E, Sarszegi Z, Szabo A, Debreceni B, Kalman N, Tucsek Z, Sumegi B, Gallyas F Jr.

PLoS One. 2013 Jun 5;8(6):e65355. doi: 10.1371/journal.pone.0065355. Print 2013.

30.

Mitigation of radiation injury by selective stimulation of the LPA(2) receptor.

Kiss GN, Lee SC, Fells JI, Liu J, Valentine WJ, Fujiwara Y, Thompson KE, Yates CR, Sümegi B, Tigyi G.

Biochim Biophys Acta. 2013 Jan;1831(1):117-25. doi: 10.1016/j.bbalip.2012.08.020.

31.

Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.

Kiss GN, Fells JI, Gupte R, Lee SC, Liu J, Nusser N, Lim KG, Ray RM, Lin FT, Parrill AL, Sümegi B, Miller DD, Tigyi G.

Mol Pharmacol. 2012 Dec;82(6):1162-73. doi: 10.1124/mol.112.079699. Epub 2012 Sep 11.

32.

TRAF6 is functional in inhibition of TLR4-mediated NF-κB activation by resveratrol.

Jakus PB, Kalman N, Antus C, Radnai B, Tucsek Z, Gallyas F Jr, Sumegi B, Veres B.

J Nutr Biochem. 2013 May;24(5):819-23. doi: 10.1016/j.jnutbio.2012.04.017. Epub 2012 Aug 24.

PMID:
22925919
33.

Hydroximic acid derivatives: pleiotropic HSP co-inducers restoring homeostasis and robustness.

Crul T, Toth N, Piotto S, Literati-Nagy P, Tory K, Haldimann P, Kalmar B, Greensmith L, Torok Z, Balogh G, Gombos I, Campana F, Concilio S, Gallyas F, Nagy G, Berente Z, Gungor B, Peter M, Glatz A, Hunya A, Literati-Nagy Z, Vigh L Jr, Hoogstra-Berends F, Heeres A, Kuipers I, Loen L, Seerden JP, Zhang D, Meijering RA, Henning RH, Brundel BJ, Kampinga HH, Koranyi L, Szilvassy Z, Mandl J, Sumegi B, Febbraio MA, Horvath I, Hooper PL, Vigh L.

Curr Pharm Des. 2013;19(3):309-46. Review.

PMID:
22920902
34.

Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation.

Radnai B, Antus C, Racz B, Engelmann P, Priber JK, Tucsek Z, Veres B, Turi Z, Lorand T, Sumegi B, Gallyas F Jr.

Mol Cancer. 2012 May 14;11:34. doi: 10.1186/1476-4598-11-34.

35.

BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases.

Sarszegi Z, Bognar E, Gaszner B, Kónyi A, Gallyas F Jr, Sumegi B, Berente Z.

Mol Cell Biochem. 2012 Jun;365(1-2):129-37. doi: 10.1007/s11010-012-1252-8. Epub 2012 Feb 14.

PMID:
22350755
36.

The HSP co-inducer BGP-15 can prevent the metabolic side effects of the atypical antipsychotics.

Literáti-Nagy Z, Tory K, Literáti-Nagy B, Kolonics A, Török Z, Gombos I, Balogh G, Vígh L Jr, Horváth I, Mandl J, Sümegi B, Hooper PL, Vígh L.

Cell Stress Chaperones. 2012 Jul;17(4):517-21. doi: 10.1007/s12192-012-0327-5. Epub 2012 Feb 10.

37.

Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease.

Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, Battyany I, Sumegi B, Toth K, Szabados E.

Clin Hemorheol Microcirc. 2012;50(3):179-87. doi: 10.3233/CH-2011-1424.

PMID:
22240353
38.

Synthesis and study of new paramagnetic resveratrol analogues.

Kálai T, Borza E, Antus C, Radnai B, Gulyás-Fekete G, Fehér A, Sümegi B, Hideg K.

Bioorg Med Chem. 2011 Dec 15;19(24):7311-7. doi: 10.1016/j.bmc.2011.10.066. Epub 2011 Oct 28.

PMID:
22088309
39.

Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.

Bartha E, Solti I, Szabo A, Olah G, Magyar K, Szabados E, Kalai T, Hideg K, Toth K, Gero D, Szabo C, Sumegi B, Halmosi R.

J Cardiovasc Pharmacol. 2011 Oct;58(4):380-91. doi: 10.1097/FJC.0b013e318225c21e.

PMID:
21697725
40.

Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients.

Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, Mikolás E, Szijártó IA, Mérei A, Halmai R, Mészáros LG, Sümegi B, Wittmann I.

Br J Nutr. 2011 Aug;106(3):383-9. doi: 10.1017/S0007114511000316. Epub 2011 Mar 9.

PMID:
21385509
41.

Induction of mitochondrial destabilization and necrotic cell death by apolar mitochondria-directed SOD mimetics.

Szabo A, Balog M, Mark L, Montsko G, Turi Z, Gallyas F Jr, Sumegi B, Kalai T, Hideg K, Kovacs K.

Mitochondrion. 2011 May;11(3):476-87. doi: 10.1016/j.mito.2011.01.006. Epub 2011 Feb 1.

PMID:
21292036
42.

Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 activation.

Racz B, Hanto K, Tapodi A, Solti I, Kalman N, Jakus P, Kovacs K, Debreceni B, Gallyas F Jr, Sumegi B.

Free Radic Biol Med. 2010 Dec 15;49(12):1978-88. doi: 10.1016/j.freeradbiomed.2010.09.026. Epub 2010 Oct 16.

PMID:
20920579
43.

Suppressing LPS-induced early signal transduction in macrophages by a polyphenol degradation product: a critical role of MKP-1.

Tucsek Z, Radnai B, Racz B, Debreceni B, Priber JK, Dolowschiak T, Palkovics T, Gallyas F Jr, Sumegi B, Veres B.

J Leukoc Biol. 2011 Jan;89(1):105-11. doi: 10.1189/jlb.0610355. Epub 2010 Sep 30.

PMID:
20884647
44.

Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disorders.

Literáti-Nagy B, Péterfai E, Kulcsár E, Literáti-Nagy Z, Buday B, Tory K, Mandl J, Sümegi B, Fleming A, Roth J, Korányi L.

Brain Res Bull. 2010 Nov 20;83(6):340-4. doi: 10.1016/j.brainresbull.2010.09.005. Epub 2010 Sep 16.

PMID:
20849938
45.

TIP47 confers resistance to taxol-induced cell death by preventing the nuclear translocation of AIF and Endonuclease G.

Hocsak E, Racz B, Szabo A, Pozsgai E, Szigeti A, Szigeti E, Gallyas F Jr, Sumegi B, Javor S, Bellyei S.

Eur J Cell Biol. 2010 Nov;89(11):853-61. doi: 10.1016/j.ejcb.2010.06.010. Epub 2010 Aug 12.

PMID:
20708296
46.

TIP47 protects mitochondrial membrane integrity and inhibits oxidative-stress-induced cell death.

Hocsak E, Racz B, Szabo A, Mester L, Rapolti E, Pozsgai E, Javor S, Bellyei S, Gallyas F Jr, Sumegi B, Szigeti A.

FEBS Lett. 2010 Jul 2;584(13):2953-60.

47.

A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: an immunohistochemical and behavioral study.

Kövesdi E, Bukovics P, Besson V, Nyirádi J, Lückl J, Pál J, Sümegi B, Dóczi T, Hernádi I, Büki A.

Int J Mol Sci. 2010 Mar 26;11(4):1253-68. doi: 10.3390/ijms11041253.

48.

Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death.

Veto S, Acs P, Bauer J, Lassmann H, Berente Z, Setalo G Jr, Borgulya G, Sumegi B, Komoly S, Gallyas F Jr, Illes Z.

Brain. 2010 Mar;133(Pt 3):822-34. doi: 10.1093/brain/awp337. Epub 2010 Feb 15.

49.

PACAP ameliorates oxidative stress in the chicken inner ear: an in vitro study.

Racz B, Horvath G, Reglodi D, Gasz B, Kiss P, Gallyas F Jr, Sumegi B, Toth G, Nemeth A, Lubics A, Tamas A.

Regul Pept. 2010 Feb 25;160(1-3):91-8. doi: 10.1016/j.regpep.2009.12.003. Epub 2009 Dec 4.

PMID:
19969027
50.

BGP-15 inhibits caspase-independent programmed cell death in acetaminophen-induced liver injury.

Nagy G, Szarka A, Lotz G, Dóczi J, Wunderlich L, Kiss A, Jemnitz K, Veres Z, Bánhegyi G, Schaff Z, Sümegi B, Mandl J.

Toxicol Appl Pharmacol. 2010 Feb 15;243(1):96-103. doi: 10.1016/j.taap.2009.11.017. Epub 2009 Nov 26.

PMID:
19931551

Supplemental Content

Loading ...
Support Center